CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

BACKGROUND: Mesothelioma is an incurable, apoptosis-resistant cancer caused in most cases by previous exposure to asbestos and is increasing in incidence. It represents a growing health burden but remains under-researched, with limited treatment options. Early promising signals of activity relating...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennell, Dean A., Kirkpatrick, Emma, Cozens, Kelly, Nye, Mavis, Lester, Jason, Hanna, Gerard, Steele, Nicola, Szlosarek, Peter, Danson, Sarah, Lord, Joanne, Ottensmeier, Christian, Barnes, Daniel, Hill, Stephanie, Kalevras, Mihalis, Maishman, Tom, Griffiths, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907297/
https://www.ncbi.nlm.nih.gov/pubmed/29669604
http://dx.doi.org/10.1186/s13063-018-2602-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907297/
https://www.ncbi.nlm.nih.gov/pubmed/29669604
http://dx.doi.org/10.1186/s13063-018-2602-y

Ejemplares similares